Source link : https://www.newshealth.biz/health-news/immunotherapy-tace-regimen-boosts-pfs-in-unresectable-liver-cancer/
SAN FRANCISCO — Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), according to results from the CARES-005 study. At a median follow-up of 13.6 months, the median PFS was 10.8 months with TACE plus camrelizumab and rivoceranib (TACE-CR) versus 3.2 months with TACE […]
Author : News Health
Publish date : 2025-01-26 13:14:51
Copyright for syndicated content belongs to the linked Source.